myelodysplastic syndromes (MDS) | Page 14 | Aplastic Anemia and MDS International Foundation

myelodysplastic syndromes (MDS)

The Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34+ Selected Grafts for Allogeneic Hematopoietic Cell Transplantation

Author(s): 
Barba P, Ratan R, Cho C, Ceberio I, Hilden P, Devlin SM, Maloy MA, Barker JN, Castro-Malaspina H, Jakubowski AA, Koehne G, Papadopoulos EB, Ponce DM, Sauter C, Tamari R, van den Brink MR, Young JW, O'Reilly RJ, Giralt SA, Perales MA
Primary Author: 
Barba P
Journal Title: 
Biol Blood Marrow Transplant
Original Publication Date: 
Oct 2016

To evaluate the association between the Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) and the recently developed age-adjusted HCT-CI (HCT-CI/age) and transplant outcomes in the setting of CD34-selected allogeneic HCT, we analyzed a homogeneous population of patients undergoing allogeneic HCT with CD34-selected grafts for acute myeloid leukemia and myelodysplastic syndrome (n= 346). Median HCT-CI and HCT-CI/age scores were 2 (percentile 25-75: 1-4) and 3 (percentile 25-75: 1-5), respectively.

Bone Marrow Diseases: 

A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia

Author(s): 
Zeidan AM, Smith BD, Carraway HE, Gojo I, DeZern A, Gore SD
Primary Author: 
Zeidan AM
Journal Title: 
Br J Haematol
Original Publication Date: 
Oct 2016

Limited therapies exist for patients with

Bone Marrow Diseases: 

San Diego Family Takes Action for Awareness

Person's Name: 
Amy Ohton

Amy Ohton speaks about her husband’s MDS and her son’s initiative to hold a swabbing drive

My husband David’s journey with MDS began in April 2014, when it was discovered almost by chance while we were on vacation. David was bitten by a brown recluse spider and had a very severe reaction to it. He had to be hospitalized, which is when he got his first blood test in years. The doctor noted that his blood counts were low and, while he didn’t rule out that the spider bite might have affected the counts, there was a possibility of myelodysplasia.

Bone Marrow Diseases: 

Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation

Author(s): 
Della Porta MG, Gallì A, Bacigalupo A, Zibellini S, Bernardi M, Rizzo E, Allione B, van Lint MT, Pioltelli P, Marenco P, Bosi A, Voso MT, Sica S, Cuzzola M, Angelucci E, Rossi M, Ubezio M, Malovini A, Limongelli I, Ferretti VV, Spinelli O, Tresoldi C, Poz
Primary Author: 
Della Porta MG
Journal Title: 
J Clin Oncol
Original Publication Date: 
Sep 2016

PURPOSE:

Bone Marrow Diseases: 

Chemical exposures and risk of acute myeloid leukemia and myelodysplastic syndromes in a population-based study

Author(s): 
Poynter JN, Richardson M, Roesler M, Blair CK, Hirsch B, Nguyen P, Cioc A, Cerhan JR, Warlick E
Primary Author: 
Poynter JN
Journal Title: 
Int J Cancer
Original Publication Date: 
Sep 2016

Bone Marrow Diseases: 

Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry

Author(s): 
Waszczuk-Gajda A, Mądry K, Machowicz R, Drozd-Sokołowska J, Stella-Hołowiecka B, Mital A, Obara A, Szmigielska-Kapłon A, Sikorska A, Subocz E, Jędrzejczak WW, Dwilewicz-Trojaczek J
Primary Author: 
Waszczuk-Gajda A
Journal Title: 
Adv Clin Exp Med
Original Publication Date: 
Aug 2016

BACKGROUND:

Bone Marrow Diseases: 

Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT

Author(s): 
Cremers EM, van Biezen A, de Wreede LC, Scholten M, Vitek A, Finke J, Platzbecker U, Beelen D, Schwerdtfeger R, Volin L, Harhalakis N, Blijlevens N, Nagler A, Kröger N, de Witte T
Primary Author: 
Cremers EM
Journal Title: 
Ann Hematol
Original Publication Date: 
Sep 2016

Many pre-transplant factors are known to influence the outcome of allogeneic stem cell transplantation (SCT) treatment in

Bone Marrow Diseases: 

Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes

Author(s): 
Zeidan AM, Davidoff AJ, Long JB, Hu X, Wang R, Ma X, Gross CP, Abel GA, Huntington SF, Podoltsev NA, Hajime U, Prebet T, Gore SD
Primary Author: 
Br J Haematol
Journal Title: 
2016 Sep 21
Original Publication Date: 
Sep 2016

The hypomethylating agents (HMAs)

Bone Marrow Diseases: